---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023194"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:20:38.427438+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q3 net loss widens to $35.3M; secures $100M loan facility, extends cash runway to mid-2025

## Summary
- GAAP net loss $35.3M ($0.87/diluted share) vs $24.6M ($0.61) in Q3 2021; non-GAAP loss $29.1M vs $20.4M.
- Cash, equivalents, investments $293.1M; $100M term loan facility ($10M drawn) extends runway to mid-2025.
- R&D expenses $29.4M (up 62% YoY) on increased clinical trial costs; G&A $7.3M (up 14%).
- Initial Phase 1 ASPEN-05 AML data showed no MTD, full CD47 occupancy, anti-leukemic activity; ASH poster Dec 12, 2022.
- New clinical trial arms: I-SPY-P1 for HER2 breast cancer (evorpacept + ENHERTU); Phase 2 CRC trial first patient dosed.

## SEC filing metadata
- accession: 0000950170-22-023194
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/0000950170-22-023194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/alxo-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023194
- JSON: https://secwatch.observer/filing/0000950170-22-023194.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023194.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/0000950170-22-023194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.